Oncology

Earlier this week, the US Preventive Services Task Force (USPSTF) released a draft guidance recommendations on medications for women at an increased risk for breast cancer.

Updates from the annual ASH meeting, December 2018.

Updates from the annual ASH meeting, December 2018.

Updates from the annual ASH meeting, December 2018.

Updates from annual ASH meeting, December 2018.

Updates from the annual ASH meeting, December 2018.

Updates from the annual ASH meeting, December 2018.

Updates from the Annual ASH meeting, December 2018.

Breast cancer risk estimation models identify women who are at high risk based on a variety of factors, and women who are identified as being at high risk may be able to reduce their chance of breast cancer through preventative measures such as prophylactic surgeries or chemoprevention medications. However, uptake of these preventative treatments varies among racial groups, new research from The Ohio State University finds that racial disparities in healthcare are to blame.

Patients with cancer who have comorbidities are less likely to have clinical trial discussions, be offered a clinical trial, and participate in a clinical trial, according to a new study.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Less than two-thirds of women aged 30 to 65 years were up to date with cervical cancer screenings in 2016. The percentage was even lower for women aged 21 to 29, with just over half up to date on screenings.

For the 25th consecutive year, the cancer mortality rate in the United States has declined, according to The American Cancer Society’s annual report on cancer rates and trends. The overall 27% drop in mortality rate translates into 2.6 million fewer deaths from cancer between the years 1991 and 2016.

New York City is expanding health coverage to 600,000 uninsured residents; a transparency rule requiring hospitals to post prices online is confusing patients; and Eli Lilly has purchased Loxo Oncology in what some are calling a massive bet on cancer genetic.

Bristol-Meyers Squibb (BMS) and Celgene kicked off the 37th Annual JP Morgan Healthcare Conference by discussing their leading drugs, near-term launches, and early pipeline assets.

Patients who are treated with chemotherapy for their solid tumors have an increased risk of therapy-related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML) despite advances in chemotherapy regimens, according to a new study in JAMA Oncology.

This week, we recapped the top news from 2018 with a look at policy changes, new research, decisions at the polls, and more.

Males with myeloproliferative neoplasms have worse survival compared with females with MPN, even when adjusted for age at presentation, presenting phenotype, and molecular characteristics.

From chimeric antigen receptor T-cell therapy to value-based contracting, reimbursement issues dominated reader interest.